Oncopeptides AB ( ($SE:ONCO) ) just unveiled an update. Oncopeptides AB announced that a panel of multiple myeloma experts has endorsed the use of ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies ...

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

In patients with symptomatic multiple myeloma, renal impairment leading to acute kidney injury (AKI) is a common complication ...

The U.S. Food and Drug Administration approved Johnson & Johnson’s drug Darzalex Faspro as the first treatment for adults with high-risk smoldering multiple myeloma, a precursor to the blood cancer.

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. The U.S. Food and ...